(Q38385719)

2 September 2017

1 reference

title

Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer (English)

1 reference

2 September 2017

1 reference

Mycobacterium bovis

1 reference

K R Begnini

1

1 reference

2 September 2017

J H Buss

series ordinal

2

1 reference

2 September 2017

T Collares

series ordinal

3

1 reference

2 September 2017

F K Seixas

series ordinal

4

1 reference

2 September 2017

language of work or name

English

0 references

publication date

21 March 2015

1 reference

Applied Microbiology and Biotechnology

2 September 2017

published in

1 reference

2 September 2017

volume

99

1 reference

2 September 2017

issue

9

1 reference

2 September 2017

page(s)

3741-3754

1 reference

https://scigraph.springernature.com/pub.10.1007/s00253-015-6495-3

2 September 2017

exact match

0 references

cites work

New agents for bacillus Calmette-Guérin-refractory nonmuscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

BCG immunotherapy of bladder cancer: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Interleukin-10 therapy--review of a new approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Bladder Cancer Immunotherapy: BCG and Beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Monocyte-derived macrophage cytokine responses induced by M. bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Recombinant Mycobacterium bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Mercury resistance as a selective marker for recombinant mycobacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full d

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

PMN and anti-tumor immunity--the case of bladder cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Genome plasticity of BCG and impact on vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

The evolution of mycobacterial pathogenicity: clues from comparative genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

The treated natural history of high risk superficial bladder cancer: 15-year outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Construction and use of integrative vectors to express foreign genes in mycobacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Superinfection immunity of mycobacteriophage L5: applications for genetic transformation of mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

IS900-promoted stable integration of a foreign gene into mycobacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Recombinant bacille Calmette-Guérin priming against measles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

BCG immunotherapy for bladder cancer--the effects of substrain differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Bladder cancer: narrowing the gap between evidence and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Introduction of foreign DNA into mycobacteria using a shuttle phasmid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Heat shock proteins and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Novel genome polymorphisms in BCG vaccine strains and impact on efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Transposition of an antibiotic resistance element in mycobacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Cancer increased after a reduction of infections in the first half of this century in Italy: etiologic and preventive implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Expression of Escherichia coli beta-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Comparison of antigen-specific T-cell responses of tuberculosis patients using complex or single antigens of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: protection against Bordetella pertussis challenge in neonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

The mechanism of action of BCG therapy for bladder cancer--a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Heat shock in Escherichia coli alters the protein-binding properties of the chaperonin groEL by inducing its phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Lysogeny and transformation in mycobacteria: stable expression of foreign genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

New use of BCG for recombinant vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Macrophages are a significant source of type 1 cytokines during mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Stress proteins, infection, and immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Mycobacterial strains that stimulate the immune system most efficiently as candidates for the treatment of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00253-015-6495-3

10.1007/S00253-015-6495-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1021172445

0 references

1 reference